Other Guidelines

Residents of long-terms facilities (LTCFs) are at great risk for infection. Most residents are older and have multiple comorbidities that recognition of infection; for example, typically defined fever is absent in more than one-half of LTCF residents with serious infection. Furthermore, LTCFs often do not have the on-site equipment or personnel to evaluate suspected infection in the fashion typically performed in acute care hospitals. In recognition of the difference between LTCFs and hospitals with regard to hosts and resources present, the Infectious Diseases Society of America first provided guidelines for Evaluation of fever and infection in LTCF residents in 2000. The guideline presented here presented here represents the second edition, updated by data generated over the intervening 8 years. Link to full text guideline

*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. This guideline was last reviewed and deemed current as of 02/2011.

In some intensive care units (ICUs), the measurement of a newly elevated temperature triggers automatic orders for many tests that are time-consuming, costly, and disruptive. Moreover, the patient may experience discomfort, be exposed to unneeded radiation, or experience considerable blood loss as a result of this testing, which is often repeated several times within 24 hours and daily thereafter. In an era when use of hospital and patient resources is under intensive scrutiny, it is appropriate to assess how such fevers should be evaluated in a prudent and cost-effective manner.

*For information on the timing of future updates to this guideline, contact SCCM.

This compendium of practice recommendations was sponsored and authored by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Partners in this work were the Association for Professionals in Infection Control and Epidemiology (APIC), the Joint Commission, and the American Hospital Association (AHA). Link to full text guideline

*Projected Publication, Spring 2014

These guidelines have been developed for healthcare personnel who insert intravascular catheters and for persons responsible for surveillance and control of infections in hospital, outpatient, and home healthcare settings. This report was prepared by a working group comprising members from professional organizations representing the disciplines of critical care medicine, infectious diseases, healthcare infection control, surgery, anesthesiology, interventional radiology, pulmonary medicine, pediatric medicine, and nursing. Link to full text guideline

*For information on the timing of future updates to this guideline, contact the SCCM.

These updated guidelines replace the previous management guidelines published in 2001. The guidelines are intended for use by health care providers who care for patients who either have these infections or may be at risk for them. Link to full text guideline 

*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. This guideline was last reviewed and deemed current as of 07/2011. 

Evidence-based guidelines for immunization of infants, children, adolescents, and adults have been prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). These updated guidelines replace the previous immunization guidelines published in 2002. These guidelines are prepared for health care professionals who care for either immunocompetent or immunocompromised people of all ages. Link to full text guideline

*For the most up to date immunization schedules, see the Advisory Committee on Immunization Practices (ACIP) recommendations.

For information on efforts by the IDSA to raise awareness about the importance of adult and adolescent immunization, healthcare worker immunization and vaccine research and development, click here.

In the past decade, modifications in HCT management and supportive care have resulted in changes in recommendations for the prevention of infection in HCT patients. These changes are fueled by new antimicrobial agents, increased knowledge of immune reconstitution, and expanded conditioning regimens and patient populations eligible for HCT. Despite these advances, infection is reported as the primary cause of death in 8% of autologous HCT patients and 17% to 20% of allogeneic HCT recipients [3]. The major changes in this document, including changes in recommendation ratings, are summarized here.

*For information on the timing of future updates to this guideline, contact CIBMTR.

For other information related to travel medicine visit the following:

CDC Travel Health Website

CDC Yellowbook

ISTM Global Travel Clinic Directory